Boulton Lab
@boultonlab.bsky.social
Our diverse lab at @crick.ac.uk studies mechanisms of DNA repair at breaks/forks/telomeres in health & disease | Tweets by lab members unless signed SB | Views own
Reposted by Boulton Lab
‼️ Excited to share our new paper out now in @science.org ‼️
We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments.
Link: www.science.org/doi/epdf/10....
Thread ⬇️ (1/8)
We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments.
Link: www.science.org/doi/epdf/10....
Thread ⬇️ (1/8)
November 7, 2025 at 10:15 AM
‼️ Excited to share our new paper out now in @science.org ‼️
We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments.
Link: www.science.org/doi/epdf/10....
Thread ⬇️ (1/8)
We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments.
Link: www.science.org/doi/epdf/10....
Thread ⬇️ (1/8)
Reposted by Boulton Lab
🧬 Preprint alert!
"Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity."
Read the manuscript here 👉 www.biorxiv.org/content/10.1...
"Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity."
Read the manuscript here 👉 www.biorxiv.org/content/10.1...
Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity
Mutations in the ATRX chromatin remodeller predispose to a developmental genetic disorder and cancer, but how it safeguards genome and telomere stability remains unresolved. Here, we uncover critical ...
www.biorxiv.org
October 7, 2025 at 9:49 PM
🧬 Preprint alert!
"Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity."
Read the manuscript here 👉 www.biorxiv.org/content/10.1...
"Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity."
Read the manuscript here 👉 www.biorxiv.org/content/10.1...
New preprint from the lab led by @ssegurabayona.bsky.social identifying SLFN11 activity as a barrier to ALT establishment.
🚀 New preprint alert!
We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.
📄 Read the manuscript here: www.biorxiv.org/content/10.1...
We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.
📄 Read the manuscript here: www.biorxiv.org/content/10.1...
SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres
The tRNA nuclease SLFN11 is epigenetically silenced in ~50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To a...
www.biorxiv.org
September 11, 2025 at 8:17 AM
New preprint from the lab led by @ssegurabayona.bsky.social identifying SLFN11 activity as a barrier to ALT establishment.
Reposted by Boulton Lab
🚀 New preprint alert!
We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.
📄 Read the manuscript here: www.biorxiv.org/content/10.1...
We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.
📄 Read the manuscript here: www.biorxiv.org/content/10.1...
SLFN11 restricts escape from telomere crisis to prevent alternative lengthening of telomeres
The tRNA nuclease SLFN11 is epigenetically silenced in ~50% of treatment-naive tumours and is the strongest predictor of chemoresistance but why it is frequently inactivated in cancer is unknown. To a...
www.biorxiv.org
September 11, 2025 at 7:23 AM
🚀 New preprint alert!
We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.
📄 Read the manuscript here: www.biorxiv.org/content/10.1...
We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis.
📄 Read the manuscript here: www.biorxiv.org/content/10.1...
Reposted by Boulton Lab
Save de date! Join us at @cabimer.bsky.social on October 17th for the @GenomaHubCSIC Workshop in "Genome Dynamics in Development and Disease". Slots available for talks! Registration opens soon!!
May 30, 2025 at 12:44 PM
Save de date! Join us at @cabimer.bsky.social on October 17th for the @GenomaHubCSIC Workshop in "Genome Dynamics in Development and Disease". Slots available for talks! Registration opens soon!!
We are looking to recruit three posts at the @crick.ac.uk in structural biology, cell biology, and pharmacology to join a 20+ strong multidisciplinary team focused on delivering the first precision medicines for the treatment of ALT cancers. Interested? Please check out the advertised jobs below:
May 27, 2025 at 9:52 PM
We are looking to recruit three posts at the @crick.ac.uk in structural biology, cell biology, and pharmacology to join a 20+ strong multidisciplinary team focused on delivering the first precision medicines for the treatment of ALT cancers. Interested? Please check out the advertised jobs below:
Reposted by Boulton Lab
Read our Q&A with Simon Boulton (@boultonlab.bsky.social), a group leader here at the Crick who co-founded the company Artios in 2016.
Artios is a biotech company that develops cancer treatments that target DNA damage response pathways.
www.crick.ac.uk/news-and-fea...
Artios is a biotech company that develops cancer treatments that target DNA damage response pathways.
www.crick.ac.uk/news-and-fea...
From the lab to the clinic: developing the next generation of precision cancer therapies
Crick group leader Simon Boulton co-founded Artios in 2016, a spin-out from Cancer Research UK’s Commercial Partnerships, where he is now VP of Science Strategy. Artios develops cancer treatments that...
www.crick.ac.uk
May 21, 2025 at 11:43 AM
Read our Q&A with Simon Boulton (@boultonlab.bsky.social), a group leader here at the Crick who co-founded the company Artios in 2016.
Artios is a biotech company that develops cancer treatments that target DNA damage response pathways.
www.crick.ac.uk/news-and-fea...
Artios is a biotech company that develops cancer treatments that target DNA damage response pathways.
www.crick.ac.uk/news-and-fea...
Reposted by Boulton Lab
Artios Pharma presented data on its ATR inhibitor (blocks a key DNA damage response enzyme) at #AACR25 today.
50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM.
Read more in my story for @endpts.com
endpts.com/artios-cance...
50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM.
Read more in my story for @endpts.com
endpts.com/artios-cance...
Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study
Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a subset of patients with advanced cancer.
endpts.com
April 29, 2025 at 8:25 PM
Artios Pharma presented data on its ATR inhibitor (blocks a key DNA damage response enzyme) at #AACR25 today.
50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM.
Read more in my story for @endpts.com
endpts.com/artios-cance...
50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM.
Read more in my story for @endpts.com
endpts.com/artios-cance...
Exciting results were presented by Artios Pharma at the AACR meeting from their STELLA Phase 1/2a study using their ATR inhibitor ART0380 to target ATM low/negative tumours: www.artios.com/press-releas...
Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Artios Pharma
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended...
www.artios.com
April 30, 2025 at 6:02 AM
Exciting results were presented by Artios Pharma at the AACR meeting from their STELLA Phase 1/2a study using their ATR inhibitor ART0380 to target ATM low/negative tumours: www.artios.com/press-releas...